Zydus Lifesciences Ltd (Zydus Lifesciences) formerly Cadila Healthcare Ltd, discovers, develops, manufactures and markets a broad range of healthcare products. Its products range from active pharmaceutical ingredients (API) to formulations, pharmaceuticals, wellness and animal health products. The company also offers a wide range of intermediates, APIs and formulations in various forms including oral dosage forms: tablets, hard and soft gel capsules; injectables: sterile liquids and lyophilised; and transdermals, inhalers, suppositories and vaccines. The branded and generics drugs provide for therapeutic areas of cardiovascular, gynecology, respiratory, gastrointestinal and dermatology.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company focuses on its research and development (R&D) activities and has a dedicated team for the development of new products. The company conducts its R&D activities through Zydus Research Centre (ZRC). ZRC conducts drug discovery and development from concept to Investigational New Drug (IND), facilitating pre-clinical and clinical development. It focuses on developing products in the areas of New Chemical Entities (NCEs) research targeted for cardio-metabolic diseases, inflammation & pain, and oncology; biologics for biosimilar therapeutic proteins biosimilar monoclonal antibodies, biobetters and novel biologics; vaccines for infectious diseases. Zydus Lifesciences operates 35 manufacturing facilities and R&D centres, which produce finished dosage formulations and APIs. As of March 31, 2023, Zydus Lifesciences filed 442 abbreviated new drug applications (ANDAs) and received approval for 364 ANDAs. In FY2023, the company filed 22 ANDAs and received approval for 63 ANDAs including nine tentative approvals. In FY2023, the company spent INR8,148 million on its R&D activities which as a percentage of revenue stood at 4.7%.